Our limited knowledge of the pathophysiology underlying mood disorders contrasts sharply with the efficacy of the treatment modalities developed over the past decades. There has been an explosion of new antidepressant and anxiolytic medications, as well as mood stabilizers and compounds that aim to improve cognition. Although treatment success is still not optimal, pharmacotherapy for mood disorders and cognitive disorders is effective and is improving. Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders takes a critical look at the medications available for treating mood, anxiety and cognitive disorders; their relevance to pathobiology and underlying mechanisms; and their limitations. Its 90 distinguished contributors, many of them pioneers in the development of treatment modalities, provide background and rationale in understanding the underlying mechanisms of frontline treatments for these disorders. This book reviews Effective new alternatives in mood stabilizers and antidepressant interventions Advances in the study of the pathobiology of anxiety disorders as well as available treatment choices, including anxiolytic medications Several treatment approaches to dementia and other age-related cognitive impairments Gender differences in the treatment of depression and anxiety and the different responses to pharmacotherapy New treatments for social phobia and pharmacological strategies for cognitive disorders
Providing both a broad overview and detailed reviews of pharmacotherapy, this resource is essential reading for any practitioner who wants to understand the rationale and background for the drugs he or she prescribes and to assess medications that are currently under development. It is a great reference and ancillary text for students and residents during their clinical years.
สารบัญ
Contributors Section I: Overviews Chapter 1. Pharmacotherapy for mood, anxiety, and cognitive disorders: An overview Chapter 2. Current theories on the pathophysiology of mood disorders Chapter 3. Pharmacological validity of diagnostic separation Chapter 4. Signal amplification in psychiatric diagnosis: Therapeutic implications Chapter 5. Gender differences in treatment of depression and anxiety Section II: Mood Stabilizers Chapter 6. Carbamazepine and nimodipine in refractory bipolar illness: Efficacy and mechanisms Chapter 7. Mechanisms of action of lithium in bipolar illness Chapter 8. Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium Chapter 9. Therapeutic potential of inositol treatment in depression, panic, dementia, and lithium side effects Chapter 10. Electroconvulsive therapy: Current practice and future directions Chapter 11. Antidepressant and mood stabilization effects potential of transcranial magnetic stimulation Section III: Antidepressants Chapter 12. Changing targets of antidepressant therapy: Serotonin and beyond Chapter 13. New emerging serotonergic antidepressants Chapter 14. Dopamine receptors and antidepressant development Chapter 15. Noradrenergic and other new antidepressants Chapter 16. Sleep in depression and the effects of antidepressants on sleep Chapter 17. Hormonal interventions as antidepressants or adjunct therapy: Treatment implications Chapter 18. Mechanisms and management of treatment-resistant depression Chapter 19. Treatment of psychotic depression Chapter 20. Antidepressant maintenance medications Section IV: Anxiolytics Chapter 21. Overview of new anxiolytics Chapter 22. Interactions between physiological, hormonal, and environmental determinants: The anxiety model Chapter 23. Serotonin-specific anxiolytics: Now and in the future Chapter 24. Serotonergic treatments for panic disorder Chapter 25. New treatments for social phobia Chapter 26. Why a peptide as an anxiolytic?Chapter 27. Cholecystokinin antagonists in panic and anxiety disorders Chapter 28. Neurosteroids Chapter 29. Nonbenzodiazepine anxiolytics acting on the GABA receptor Chapter 30. Treatment of obsessive-compulsive disorder: From theory to practice Chapter 31. New approaches to treatment-refractory obsessive-compulsive disorder Section V: Cognition and Dementia Chapter 32. Pharmacological strategies for cognitive disorders: An overview Chapter 33. Cholinergic approaches to cognition and dementia Chapter 34. Serotonin mechanisms and cognition Chapter 35. Nicotinic cholinergic approaches to cognitive enhancement in the dementias References Index
เกี่ยวกับผู้แต่ง
Uriel Halbreich, M.D., is Professor of Psychiatry, Research Professor of Gynecology and Obstetrics, and Director of Biobehavioral Research at the State University of New York at Buffalo.Stuart A. Montgomery, M.D., is Professor of Psychiatry in the Department of Pharmacology at St. Mary’s Hospital Medical School in London, England.
หนังสืออิเล็กทรอนิกส์เพิ่มเติมจากผู้แต่งคนเดียวกัน / บรรณาธิการ
11,620 หนังสืออิเล็กทรอนิกส์ในหมวดหมู่นี้
